TapImmune Inc.

161 articles with TapImmune Inc.

• TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing

  10/17/2018

  TapImmune Inc. (NASDAQ: TPIV), today announced the closing of the previously announced merger with privately-held Marker Therapeutics, Inc. 

• TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

  10/10/2018

  Mayo Clinic Receives $11 Million to Study TPIV110 in Combination with Trastuzumab (Herceptin®)

• TapImmune to Present at Two Upcoming October 2018 Investor Conferences

  9/25/2018

  TapImmune Inc. today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming investor conferences. Mr. Hoang will present at the Cantor Global Healthcare Conference, to be held October 1-3, 2018

• TapImmune to Participate at Two Upcoming September 2018 Industry Conferences

  8/29/2018

  TapImmune Inc. will participate at two upcoming industry conferences.

• TapImmune Announces Pricing of $70 Million Private Placement

  6/8/2018

  TapImmune Inc. today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities.

• TapImmune to Present at the Jefferies 2018 Global Healthcare Conference

  5/31/2018

  TapImmune Inc. announced that its President and CEO, Peter L. Hoang, will present at the Jefferies 2018 Global Healthcare Conference.

• TapImmune to Present at 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum

  5/30/2018

  TapImmune Inc. will participate in a panel discussion and give a company presentation at the 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum.

• TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center

  5/22/2018

  TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has expanded its recently formed Scientific Advisory Board (SAB) and will support the continued clinical development of the Company's transformative, non-genetically engineered, multi-antigen T cell therapy platform.

• TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform

  5/16/2018

  Welcomes Renowned Thought Leaders Dr. Malcolm Brenner, Dr. Helen Heslop, and Dr. Cliona Rooney

• TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform

  5/15/2018

  TapImmune Inc. (NASDAQ: TPIV) ("TapImmune") today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. ("Marker"), a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.

• TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference

  5/1/2018

  TapImmune Inc. announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Disruptive Growth & Healthcare Conference, held May 8-9, 2018 at Reed Smith LLP in New York City.

• TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research

  3/15/2018

  Phase 1 Demonstration of Safety and Long-Lasting Immune Responses in Ovarian and Breast Cancer Conference Call and Live Audio Webcast Scheduled for Today at 9:00 AM ET to Discuss the Results

• TapImmune to Present at Two Upcoming Investor Conferences

  3/14/2018

  TapImmune Inc. announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the Sachs BioCapital USA Forum, held March 21st, 2018.

• TapImmune Announces Enrollment of First Patient in Phase II Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense

  12/12/2017

  The 280-patient trial, sponsored by Mayo Clinic, received $13.3M in grant funding from the DoD to evaluate the prevention of cancer recurrence in women with TNBC who have completed first-line surgery and radiotherapy/chemotherapy.

• TapImmune Appoints Richard Kenney, M.D., F.A.C.P., as Acting CMO

  12/6/2017

  In this newly created role at TapImmune, Dr. Kenney will continue to manage the Company's ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates.

• TapImmune Provides Third Quarter 2017 Corporate and Clinical Update

  11/16/2017

  A public conference call and live audio webcast is scheduled for today at 4:30 p.m. ET.

• TapImmune to Provide Third Quarter 2017 Business Update Conference Call and Webcast

  11/14/2017

  The event will be webcast live via the Internet on: November 15, 2017 4:30 p.m. ET

• TapImmune Completes Patient Enrollment Ahead of Schedule in Phase II Cancer Vaccine Study for Treating Triple-Negative Breast Cancer

  11/14/2017

  The comprehensive four-arm study is designed to help determine the optimal vaccine dose and regimen to maximize the immune response generated against the vaccine's molecular target, FRa.

• A Personal Letter to the Shareholders From TapImmune's New Chief Executive Officer

  10/18/2017

  TapImmune announces a letter from the CEO.

• TapImmune Brings on Former Bellicum Exec as New CEO

  9/25/2017